Ribociclib
Kisqali With an AI and Kisqali Femara Co-Pack Approved for Early High-Risk Breast Cancer
The FDA has approved Kisqali with an aromatase inhibitor for the adjuvant treatment of adults with HR-positive, ...
SEPTEMBER 17, 2024
FDA Expands Breast Cancer Indications for Kisqali
The FDA expanded the indications for ribociclib (Kisqali, Novartis) in the treatment of patients with hormone ...
JULY 20, 2018
Kisqali Approved as First-Line Therapy for HR+/HER2-Metastatic Breast Cancer
Kisqali is a selective CDK4/6 inhibitor, a class of drugs that help slow the progression of cancer by inhibiting ...
MARCH 14, 2017
Load more